Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Although the selective serotonin reuptake inhibitors (SSRIs), which are now widely used as a first-line treatment for depression and many other psychiatric conditions, are generally well tolerated, they are not devoid of side effects. Most short-term treatment-related side effects of SSRIs are transient and disappear after a few days or weeks. However, following long-term treatment with the SSRIs, some serious adverse events may occur. Some of them can be difficult to recognise because they can resemble residual symptoms of depression. The most serious can be life threatening. They all have a negative influence on the patient's quality of life and are frequently a prime reason for a lack of long-term compliance with the associated increased risk of recurrence of a depressive episode. This article is an overview of the more common adverse events, which are seen with non-acute treatment with the SSRIs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional potential challenges include continuation of medication during pregnancy [17] and potential drug interactions [13].”
From Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods (2018) · cites this paper as [13]
In the citing paper
“Although widely used and efficacious [8–10], SRI use long-term is associated with adverse side effects [11–14]”
From Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods (2018) · cites this paper as [13]
In the citing paper
“Psilocybin is typically administered for a few weeks, a considerably shorter duration compared to treatment with SSRIs/SNRIs, which can last several months or years to show and maintain antidepressant effects. 102”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [102]
In the citing paper
“but safety assessment is inherently biased by certain methodological weaknesses of RCTs.These weaknesses include small and unrepresentative samples, rare and inconsistent reporting of adverse outcomes, and short duration of exposures.14,15”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [14]
In the citing paper
“However, SSRIs and SNRIs are associated with a range of side effects, including loss of appetite, weight loss, drowsiness, dizziness, fatigue, headaches, increased suicidal thoughts, nausea/vomiting, sexual dysfunction, and increased risk of cardiovascular and cerebrovascular events [3–5].”
From Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report (2021) · cites this paper as [4]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn
Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L., & Mitchell, A. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052744 · Cited by 880
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 3×
“On the contrary, sertraline tends to reduce nocturnal wakening (Ferguson, 2001).”
BackgroundInfluentialEffects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Association of road-traffic accidents with benzodiazepine use
Barbone, F., McMahon, A., Davey, P., Morris, A., Reid, I., McDevitt, D., & MacDonald, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04087-2 · Cited by 559
Emergence of intense suicidal preoccupation during fluoxetine treatment
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.207 · Cited by 532
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
Louik, C., Lin, A. E., Werler, M. M., Hernández-Díaz, S., & Mitchell, A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067407 · Cited by 500
Research works printed but not linked: 13
- George, MS, 1992, J Clin Psychiatry, 53, 379
- Guay, D., 2000, Consult Pharm, 15, 160
- Gumnick, JF, 2000, J Clin Psychiatry, 61, 5
- Hoehn-Saric, R., 1991, J Clin Psychiatry, 52, 131
- Kelsey, JE ( 2001) Mood disorders. In: Rakel, RE, Bope, ET (eds), Conn’s Current Therapy. Philadelphia: WB Saunders Company, pp. 1147-1154.
- Lerner, UH, 2005, Lakartidningen, 102, 2746
- Lieberman, JA, 2003, Prim Care Companion J Clin Psychiatry, 5, 6
- 10.3109/hrp.7.2.69 · doi:10.3109/hrp.7.2.69 · Paper page
- Odar-Cederlöf, I., 2006, Lakartidningen, 103, 1112
- Richelson, E., 1996, J Clin Psychiatry, 16, 1S
- Rothschild, AJ, 1991, J Clin Psychiatry, 52, 491
- Ryan, D., 2005, Can Fam Physician, 51, 1087
- 10.1016/s0140-6736(05)70271-3 · doi:10.1016/s0140-6736(05)70271-3 · Paper page
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“There are, however, safety issues with SSRIs that require caution (Moret et al., 2009; Roose and Miyazaki, 2005).”
BackgroundCarvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Hudak, R., & Gannon, J. M. (2022) · Current Clinical Practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
Metadata
- Authors
- Moret, C., Isaac, M., & Briley, M.
- Affiliations
- NeuroBiz Consulting & Communication, Castres, France,
- South London and Maudsley NHS Foundation Trust (GB)
- NeuroBiz Consulting & Communication, Castres, France
- Corresponding author
- Moret, C.
- ORCID
- Isaac, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-07-17
- Volume
- 23
- Issue
- 8
- Pages
- 967-974
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2006895116
- Cited by
- 135
- References
- 87
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 10 · 2020: 11 · 2019: 6 · 2018: 10 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 10
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- selective serotonin reuptake inhibitors, long-term treatment, adverse drug reactions, antidepressant side effects, depression, medication adherence, depression recurrence, quality of life
- MeSH terms
- Adult, Child, Female, Fetus, Gastrointestinal Hemorrhage, Humans, Hyponatremia, Infant, Newborn, Neonatal Abstinence Syndrome, Pregnancy, Sexual Behavior, Sleep Wake Disorders, Suicide, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. https://app.cochat.ai/papers/10.1177/0269881108093582
- The paper
- Moret, C., Isaac, M., & Briley, M. (2009). Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. Journal of Psychopharmacology. https://doi.org/10.1177/0269881108093582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.